Adial Pharmaceuticals, Inc. - ADIL Forward P/E Multiple

Corporate company logo of Adial Pharmaceuticals Inc. (ADIL)

Adial Pharmaceuticals (ADIL) is implementing ESG standards in the fight against addiction by developing personalized medications based on patient DNA. However, capital shortages and FDA requirements are hindering final testing. The company's future P/E ratio on GURU.Markets reflects these fundamental factors, while the 0.00 metric determines this parameter level, linking market expectations with projected earnings.

Future Price to Earnings Multiple: adialpharma.com (ADIL) for 07/04/2022 - 10/29/2026

Analytical breakdowns for Adial Pharmaceuticals

- stock quotes and analyst forecast:
Stock Price Adial Pharmaceuticals|ADIL - Forecast Levels Chart
- issuer market value details:
Market Capitalization Adial Pharmaceuticals Inc.|ADIL - Enterprise Value
- book capitalization information:
Net Assets per Single Share Adial Pharmaceuticals|ADIL - Accounting Value of Company|Market Value to Book Value Ratio adialpharma.com|ADIL - Cumulative Company Assets
- company liabilities and liquidity data:
Total Debt to Capital Adial Pharmaceuticals|ADIL - Long-Term Debt to Capital|Short-Term Debt to Capital Adial Pharmaceuticals|ADIL - Company Aggregate Debt|Debts to Book Capitalization Adial Pharmaceuticals Inc.|ADIL - Long-Term Debt Volume|Company Short-Term Debts Adial Pharmaceuticals|Quick Liquidity adialpharma.com
- company profitability and valuation multiples indicators:
ADIL - Company Net Income|Future Profit Adial Pharmaceuticals|ADIL - Company Value to Net Income|Future Price to Earnings Adial Pharmaceuticals|ADIL - Market Cap to Earnings and Growth Ratio|EV/EBITDA Multiple Adial Pharmaceuticals Inc.|ADIL - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Adial Pharmaceuticals|ADIL - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months adialpharma.com|ADIL - Earnings per share increase in current year|Net earnings per share growth forecast for next year Adial Pharmaceuticals
- sales volume and revenue information:
ADIL - Company Sales|Projected Sales Volume Adial Pharmaceuticals|ADIL - P/S Multiple|Forward P/S Multiple Adial Pharmaceuticals Inc.
Summary company analytics:Adial Pharmaceuticals, Inc.
Brand item of Adial

Professional capital evaluates Adial Pharmaceuticals (ADIL) through the lens of the future value of innovations in neurogenetics and addiction therapy. By analyzing the company's expected P/E multiple, the investor compares the market price with projected earnings, which allows for the identification of the asset's real value and the distinction between fundamental growth and temporary price undervaluation, thereby determining the ultimate reliability of the investment.

Main competitors

Forward P/E Multiple INDV|COLL: Price to Expected Earnings Ratio|Forward P/E Multiple CRON (Cronos)|Forward P/E Multiple Canopy Growth Corp. CGC|HITI - Future Price to Earnings|Future Price to Earnings Multiple ACB (Aurora Cannabis)|Achieve Life Sciences, Inc. (ACHV) - Future Price to Earnings|Projected Price to Earnings Skye Bioscience Inc.|ANEB (Anebulo) - Forward P/E Multiple|Forward P/E Multiple Canndoc|Forward P/E Multiple NTRB|nasuspharma.com - Price to Future Earnings Ratio|Forward P/E Multiple IGC (IGC Pharma)|Market Cap to Projected Earnings MIRA Pharmaceuticals Inc. (MIRA)|Flora Growth Corporation - Forward P/E Multiple|IMCC - Forward P/E Multiple|artelobio.com (ARTL) - Future Price to Earnings|ENSC (Ensysce Biosciences, Inc.) - Future Price to Earnings|Projected Price to Earnings TTNP|GNLN: Future Price to Earnings Multiple|Future Price to Earnings InMed Pharma (INM)|AKAN: Price to Expected Earnings Ratio|Forward P/E Multiple ENVB (Enveric Biosciences)|Future Price to Earnings Multiple BGXX|Hempacco Co., Inc. - Forward P/E Multiple